Makes heart valves for cardiovascular disease patients.
Jun 2026Revenue $6.51B/yrExpenses $5.06B/yr
Expected to fall below break-even Oct 2031
Figures by year
Is Edwards Lifesciences still profitable?
Yes. In the 12 months to Jun 2026, revenue was $6.51B and expenses $5.06B. Its expenses are growing faster than its revenue, and the trends are projected to cross in Oct 2031.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.07B | $4.80B | $1.26B |
| Dec 2024 | $5.44B | $4.06B | $1.38B |
| Dec 2023 | $5.01B | $3.70B | $1.31B |
| Dec 2022 | $4.46B | $2.97B | $1.50B |
| Dec 2021 | $5.23B | $3.54B | $1.69B |
| Dec 2020 | $4.39B | $3.49B | $898M |
| Dec 2019 | $4.35B | $3.20B | $1.15B |
| Dec 2018 | $3.72B | $2.97B | $748M |
| Dec 2017 | $3.44B | $2.35B | $1.09B |
| Dec 2016 | $2.96B | $2.21B | $751M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.